Hypolipidemic agent. Exhibits higher potency than nicotinic acid and clofibrate. Full and potent agonist at the human orphan GPCR HM74A/GPR109A and GPR109B (EC50
values are 1.3�and 4.2 μ
M respectively). Reduces serum triglycerides and circulating LDL-cholesterol in vivo
, without affecting liver weight or liver enzymes.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Evaluation of the lipid-lowering activity of AY-25,712 in rats.
Cayen et al.
Analogues of acrifan: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
Jung et al.
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
Jirkovsky and Cayen
Molecular identification of high and low affinity receptors for nicotinic acid.
Wise et al.